News | August 11, 2021
Cadila Healthcare net profit at Rs 587.2 cr in Q1FY22
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
Company working on COVID vaccine INO 4800
Filing for WHO Emergency Use Authorisation this month
This robust growth has come despite the raging pandemic for most part of the quarter
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
Earlier, the USFDA has granted ‘Orphan Drug Designation’ and ‘Fast Track Designation’ to Saroglitazar Mg for PBC
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
Subscribe To Our Newsletter & Stay Updated
